XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Total RadNet, Inc.'s Equity
Common Stock
Common Stock
Equity Incentive Plan
Common Stock
DeepHealth, Inc.
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2023     67,956,318            
Beginning balance at Dec. 31, 2023 $ 813,359 $ 630,695 $ 7     $ 722,750 $ (12,484) $ (79,578) $ 182,664
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     60,605            
Issuance of common stock upon exercise of options 367 367       367      
Issuance of common stock under the equity compensation plan (in shares)       657,887 9,377        
Issuance of common stock, net of issuance costs (in shares)     5,232,500            
Issuance of common stock, net of issuance costs 218,385 218,385 $ 0     218,385      
Stock-based compensation expense 16,679 16,679       16,679      
Forfeiture of restricted stock and share cancellation (in shares)     (43,664)            
Forfeiture of restricted stock and share cancellation (34) (34)       (34)      
Sale of economic interests in majority owned subsidiary, net of taxes 13,517               13,517
Issuance of common stock in connection with acquisitions (in shares)     95,019            
Issuance of common stock in connection with acquisitions   4,607       4,607      
Distributions paid to noncontrolling interests (2,423)               (2,423)
Contributions from noncontrolling interests 11,601 11,601       11,601     0
Change in cumulative foreign currency translation adjustment (2,829) (2,829)         (2,829)    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 7,256 7,256         7,256    
Net (loss) income 12,355 (5,761)           (5,761) 18,116
Ending balance (in shares) at Jun. 30, 2024     73,968,042            
Ending balance at Jun. 30, 2024 1,092,840 880,966 $ 7     974,355 (8,057) (85,339) 211,874
Beginning balance (in shares) at Mar. 31, 2024     73,901,654            
Beginning balance at Mar. 31, 2024 1,077,325 872,955 $ 7     969,248 (13,943) (82,357) 204,370
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     59,306            
Issuance of common stock upon exercise of options 359 359       359      
Issuance of common stock under the equity compensation plan (in shares)       41,120 4,984        
Stock-based compensation expense 4,773 4,773       4,773      
Forfeiture of restricted stock and share cancellation (in shares)     (39,022)            
Forfeiture of restricted stock and share cancellation (25) (25)       (25)      
Distributions paid to noncontrolling interests (2,423)               (2,423)
Change in cumulative foreign currency translation adjustment (631) (631)         (631)    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 6,517 6,517         6,517    
Net (loss) income 6,945 (2,982)           (2,982) 9,927
Ending balance (in shares) at Jun. 30, 2024     73,968,042            
Ending balance at Jun. 30, 2024 $ 1,092,840 880,966 $ 7     974,355 (8,057) (85,339) 211,874
Beginning balance (in shares) at Dec. 31, 2024 74,036,993   74,036,993            
Beginning balance at Dec. 31, 2024 $ 1,133,410 902,308 $ 7     988,147 (9,061) (76,785) 231,102
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares) 62,296   62,296            
Issuance of common stock upon exercise of options $ 555 555 $ 1     554      
Issuance of common stock under the equity compensation plan (in shares)       970,712 3,438        
Stock-based compensation expense 37,275 37,275       37,275      
Forfeiture of restricted stock and share cancellation (in shares)     (6,337)            
Forfeiture of restricted stock and share cancellation (40) (40)       (40)      
Distributions paid to noncontrolling interests (3,313)               (3,313)
Contributions from noncontrolling interests 2,389               2,389
Change in cumulative foreign currency translation adjustment 13,632 13,632         13,632    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 2,056 2,056         2,056    
Net (loss) income $ (6,703) (23,472)           (23,472) 16,769
Ending balance (in shares) at Jun. 30, 2025 75,067,102   75,067,102            
Ending balance at Jun. 30, 2025 $ 1,179,261 932,314 $ 8     1,025,936 6,627 (100,257) 246,947
Beginning balance (in shares) at Mar. 31, 2025     74,956,566            
Beginning balance at Mar. 31, 2025 1,136,517 898,139 $ 7     1,016,762 (3,919) (114,711) 238,378
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock upon exercise of options (in shares)     50,340            
Issuance of common stock upon exercise of options 434 434 $ 1     433      
Issuance of common stock under the equity compensation plan (in shares)       63,877          
Stock-based compensation expense 8,761 8,761       8,761      
Forfeiture of restricted stock and share cancellation (in shares)     (3,681)            
Forfeiture of restricted stock and share cancellation (20) (20)       (20)      
Distributions paid to noncontrolling interests (2,400)               (2,400)
Contributions from noncontrolling interests 2,389               2,389
Change in cumulative foreign currency translation adjustment 9,523 9,523         9,523    
Change in fair value of cash flow hedge from prior periods reclassified to earnings 1,023 1,023         1,023    
Net (loss) income $ 23,034 14,454           14,454 8,580
Ending balance (in shares) at Jun. 30, 2025 75,067,102   75,067,102            
Ending balance at Jun. 30, 2025 $ 1,179,261 $ 932,314 $ 8     $ 1,025,936 $ 6,627 $ (100,257) $ 246,947